Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Peter Singleton who wrote (3812)	2/12/1998 11:48:00 AM
From: margie	Read Replies (1) of 6136

When Roche ended it's collaboration with Agouron, both Agouron and PW stated that they believed that Roche's decision to discontinue the program reflected a longer-term strategic assessment based upon Roche's intended acquisition of Boehringer Mannheim/Corange. Many were skeptical of this at the time. There is an excellent article at recap.com called The Ripple Effect, about the SmithKline/Glaxo merger and it's effect on collaborations that each company has with hundreds of biotechnology companies. "The SmithKline/Glaxo merger talks throw a spotlight on an ongoing biotech predicament." "Alliances with pharmaceutical companies have been the salvation of many biotechnology companies. But as the giants struggle with enormous pressures to deliver growth to Wall Street and seek their own salvation with mega-mergers, projects with biotech companies are often left to twist in the winds of uncertainty -- or just flat-out dropped. Product champions may be lost or shunted aside. Management is distracted. Research priorities are reset. Internal projects at a merger partner get the nod over external collaborations. With British drug powerhouses SmithKline and Glaxo on the verge of creating the world's largest pharmaceutical company in a merger that would result in an entity selling 7.5% of the world's drugs, it's safe to say dozens of biotechnology executives involved in at least 200 different alliances the two giants have forged in recent years, are waiting for the phone to ring -- and are a bit afraid to answer it." signalsmag.com Off topic: sort of... John W: All the protease inhibitors have side effects. some more than others. It is possible that more cases of 'crix belly' MAY be reported, as awareness of the condition grows. Abstract 411 found at least one patient using each of the protease inhibitors, including Nelfinavir, developed a 'cervical fat pad." What we don't really need is this mentality of 'my protease inhibitor is better than yours' or 'my company is better than yours.'

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next